An antibody, αIR3, directed against the IGF receptor, IGF1R, blocked IGF activity and tumour growth in xenograft models of human breast cancer, but the antibody had some agonist activity and cross-reactivity with the insulin receptor (Kato et al, 1993). Here, IGF1R is linked to neoplasm.